睿知中国医院研究地图
候选清单

正在招募鼻咽癌II/III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06241599,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 1

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(1 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06241599,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years and ≤75 years; 2. Non-keratinized differentiated or undifferentiated nasopharyngeal carcinoma confirmed by pathology; 3. For patients with recurrent and metastatic nasopharyngeal carcinoma who are not eligible for local treatment and meet the definition of the staging system (8th edition) of the International Union against Cancer and the American Joint Committee on Cancer (UICC/AJCC), local treatment mainly refers to measures related to anti-tumor treatment, including surgery, radiofrequency ablation, transhepatic arterial chemoembolization (TACE), radiotherapy (except for patients with bone metastasis). A locally appropriate dose of radiotherapeutic therapy for symptomatic relief) 4. Patients with nasopharyngeal carcinoma recurrence and metastasis who failed first-line treatment; 5.ECOG performance score 0 or 1; 6. There is at least one measurable lesion according to the RECIST1.1 evaluation criteria, and a lesion that has previously received, for example, radiation therapy can be considered a target lesion if there is objective evidence of disease progression. 7. Patients are required to provide tissue samples within three years prior to enrollment; 8. Expected survival ≥3 months; 9. The functions of vital organs meet the following requirements (no blood components, cell growth factors, whitening drugs, thrombocytophytics, or anemia correction drugs are allowed within 14 days before screening) : · Neutrophil absolute count (ANC) ≥1.5×109/L· Platelets ≥100×109/L; · Hemoglobin ≥8.0g/dl (note: Hemoglobin ≥8.0g/dl through blood transfusion or other intervention is acceptable); · Serum albumin ≥2.8g/dL; · Bilirubin ≤ 1.5x ULN, ALT and AST≤ 1.5x ULN; If there is liver metastasis, ALT and AST are less than 5 times ULN. Creatinine clearance ≥50mL/min (using the standard CockcroftGault formula, see Annex II); 10. Women of reproductive age who have an unsterilized sexual partner should use at least one highly effective form of birth control; 11. Unsterilized men with a partner of childbearing age must use a highly effective form of birth control from day 1 to day 120 of the last use of the study drug; 12. Informed consent has been signed.

排除标准:Exclusion Criteria:

  1. Previous history of allergy to 5-Fu, cisplatin, gemcitabine, other monoclonal antibodies or any component of CTLA-4 and PD1 bispecial antibodies; In the past, CTLA-4 and PD1-specific antibody therapy were used simultaneously. 2. Had major surgery other than diagnosis of nasopharyngeal cancer within 28 days prior to randomization or was expected to require major surgery during the study period; 3. The subject has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or asthma that has been in complete remission in childhood can be adults without any intervention.Patients with asthma requiring medical intervention with bronchodilators were not included); 4. Subjects were taking immunosuppressants, or systemic, or absorbable local hormone therapy for immunosuppressive purposes (doses >10mg/ day of prednisone or other therapeutic hormones) and continued to use within 2 weeks prior to enrollment; 5. Known subject is previously allergic to macromolecular protein preparation ingredients; 6. The subject has clinically symptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or progression of brain metastases); Other aggressive malignancies within 7.5 years, except locally curable (appearing to cure) malignancies such as basal or squamous cell carcinoma of the skin, superficial cancers of the bladder, cervix and breast in situ; 8. Active autoimmune disease requiring systemic treatment within the last two years, except vitiligo, alopecia, Grave disease, psoriasis or eczema that did not require systemic treatment within the last two years, hypothyroidism requiring stable hormone replacement therapy only (due to autoimmune thyroiditis), type 1 diabetes requiring stable dose insulin replacement therapy only; Childhood asthma that has been completely cured in adulthood without intervention or primary disease that does not recur unless stimulated by external factors; 9. Active or previous inflammatory bowel disease (such as Crohn's disease, ulcerative colitis, or chronic diarrhea); 10. Systemic glucocorticoid therapy (dose equivalent to 10mg/ day of prednisone) or other immunosuppressants are required within the first seven days of initial administration of the investigational drug. 11. Having allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 12. Gastrointestinal perforation or fistula within the first six months of enrollment; 13. There were necrotic foci within the first four weeks of enrollment that researchers thought might be a potential source of major bleeding;14. History of interstitial pneumonia; 15. History of active tuberculosis; 16. Serious infections, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia, occur within four weeks prior to the first application of the investigational drug; 17. Active infections that require systematic treatment; 18. Untreated chronic hepatitis B or chronic HBVDNA≥1000IU/ml or active hepatitis C. Non-active HBsAg carriers, stable hepatitis B after treatment (HBVDNA < 1000IU/ml) and cured hepatitis C can be included. Patients who are positive for HCV antibodies can only be enrolled if they test negative for HCVRNA. 19. History of major surgery within 30 days before the first application of the investigational drug; 20. There is meningeal metastasis or active brain metastasis; 21. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; 22. Toxicity problems unresolved at the time of previous antitumor therapy, defined as unresolved to level 0 or 1 of NCICTCAEv5.0, or levels specified in the inclusion/exclusion criteria, except hair loss. 23. Live attenuated vaccines were administered within 30 days prior to the first application of the investigational drug, or live attenuated vaccines were planned to be administered during the study period. 24. Known history of severe allergy to other monoclonal antibodies; 25. Pregnant or lactating women; 26. Have clinical symptoms or diseases of heart that are not well controlled, such as: ① heart failure of NYHA2 or above; ② Unstable angina pectoris; ③ Myocardial infarction occurred within 1 year; Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; 27. Subjects had an active infection or unexplained fever >38.5 degrees during screening or prior to initial dosing (as determined by the investigator, subjectsFever due to tumor can be included in the group); •28. Allergic to AK104 ingredients; 29. The subject has a known history of psychotropic substance abuse, alcohol abuse, or drug use; 30. According to the investigator's judgment, the subjects have other factors that may lead to the forced termination of the study, such as other serious illnesses (including mental illness) requiring combined treatment, serious abnormalities in laboratory tests, and family or social factors that may affect the safety of the subjects, or the collection of test data and samples.

引自 ClinicalTrials.gov, NCT06241599, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06241599,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06241599